Google
PBMWW — PSYENCE BIOMEDICAL LTD. WARRANT
PBMWW FAQ
What is PBMWW's ROE?
PSYENCE BIOMEDICAL LTD. WARRANT reports a Return on Equity (ROE) of -212.63%.
What is PBMWW's dividend yield?
PSYENCE BIOMEDICAL LTD. WARRANT offers a dividend yield of 0.00%.
What is PBMWW's Deepscope Quality Score?
Deepscope rates PBMWW's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PBMWW?
Deepscope's AI Timing Score for PBMWW is 5 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
|
USD 0.03
Price
-0.01
(-13.50%)
Day Change
|
|
|---|
PBMWW, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 65 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.03 |
| PBV / Sector |
N/A / N/A
|
| Earning Per Share | N/A |
| PE / Sector |
N/A / N/A
|
| PEG or PE/Growth / Sector |
N/A / N/A
|
| Average 1M Daily Value |
1022.010900000000
|
| Average 1W Daily Value |
653.045200000000
|
| Timing Factors |
|
71% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
8% |
| Registration Details |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 121 Richmond Street West, Toronto, ON, Canada, M5H2K1
Phone: 416 346 7764
Website: https://www.psyencebiomed.com
Sector: -
Description: Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
ME vs SECTOR
Click a bubble to view stock details · Bubble size represents market capitalization share
